STS抗体;STS Antibody—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Hela cell lysate, Primary antibody: P12244(STS Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P12244(STS Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

STS antibodies, primarily associated with anti-synthetase syndrome (ASS), are a group of autoantibodies targeting aminoacyl-tRNA synthetases—enzymes critical for protein synthesis. The most common is anti-Jo-1 (histidyl-tRNA synthetase), though others like anti-PL-7. anti-PL-12. and anti-EJ are also recognized. These antibodies are linked to a rare autoimmune disorder characterized by inflammatory myositis (muscle inflammation), interstitial lung disease (ILD), arthritis, fever, Raynaud’s phenomenon, and mechanic’s hands.

First identified in the 1980s, STS antibodies serve as diagnostic markers for ASS, aiding differentiation from other connective tissue diseases. Their presence often correlates with severe pulmonary involvement, necessitating early intervention. Pathogenesis involves molecular mimicry or aberrant immune activation, leading to autoantibody production and tissue damage. Diagnosis combines antibody detection (via ELISA or immunoprecipitation) with clinical features. Treatment focuses on immunosuppression (e.g., corticosteroids, rituximab) and managing ILD. Prognosis varies, with outcomes depending on timely diagnosis and organ-specific complications. Research continues to explore targeted therapies and mechanisms driving autoimmunity in STS-positive patients.